Clinical trials: BCC
Basal Cell Carcinoma
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
This is a prospective single-center, open label, pilot study to investigate the safety and efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.
- Trial name
- NCT01529450
- Testing
- LDE225
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Anne Chang
Basal Cell Carcinoma (BCC), Skin Cancer
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Basal cell carcinomas (BCCs) are the most common human cancer in the US and affect over 1 million people. There is no effective drug to prevent basal cell carcinomas of the skin.
- Trial name
- NCT01108094
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Stanford University
Neoplastic Syndrome
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00489086
- Testing
- tazarotene
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland